leisure time -WSS

leisure time

author：entertainment 2025-09-06 02:05:54 - browse：657

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Listen: PBM conflicts, RSV vaccines, & the future of flu season

leisure time

focus

WSS

Option Care buys Amedisys in $3.6 billion home care deal

4th of July breaks record for highest global temperature ever measured

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Doctor appointment wait times are getting worse

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

New air purifier tech could be key to improving indoor air quality

Community addresses injustice for Long Island mothers

Medical leaders decry Supreme Court decision on affirmative action

Inside the fall of star MIT scientist David Sabatini

Jerome Adams on the need for new antivirals for Covid

Why is France rioting? What to know about the fatal police shooting of Nahel M

In Memoriam: Notable people who died in 2023

Problems with a popular proposal to regulate AI in health care

Guidelines to prevent youth baseball injuries need more muscle

A protest over insulin prices is seen as a fight for life

focus

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

340B reform proposal comes out of Senate working group

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Did the public have the right to know Arthur Ashe had AIDS?

Cano Health’s bankruptcy is a warning for Medicare Advantage

RaDonda Vaught case: a double standard for nurses, physicians

entertainment

leisure time

focus

knowledge